- Home
- THCH vs ADVM Comparison
THCH vs ADVM Comparison
Compare THCH & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THCH
- ADVM
- Stock Information
- Founded
- THCH 2018
- ADVM 2006
- Country
- THCH China
- ADVM United States
- Employees
- THCH N/A
- ADVM N/A
- Industry
- THCH Blank Checks
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- THCH Finance
- ADVM Health Care
- Exchange
- THCH Nasdaq
- ADVM Nasdaq
- Market Cap
- THCH 84.2M
- ADVM 94.6M
- IPO Year
- THCH N/A
- ADVM 2014
- Fundamental
- Price
- THCH $2.62
- ADVM $4.93
- Analyst Decision
- THCH
- ADVM Strong Buy
- Analyst Count
- THCH 0
- ADVM 4
- Target Price
- THCH N/A
- ADVM $19.75
- AVG Volume (30 Days)
- THCH 14.4K
- ADVM 746.8K
- Earning Date
- THCH 11-11-2025
- ADVM 11-03-2025
- Dividend Yield
- THCH N/A
- ADVM N/A
- EPS Growth
- THCH N/A
- ADVM N/A
- EPS
- THCH N/A
- ADVM N/A
- Revenue
- THCH $187,316,342.00
- ADVM $1,000,000.00
- Revenue This Year
- THCH N/A
- ADVM $1,449.40
- Revenue Next Year
- THCH N/A
- ADVM N/A
- P/E Ratio
- THCH N/A
- ADVM N/A
- Revenue Growth
- THCH N/A
- ADVM N/A
- 52 Week Low
- THCH $1.95
- ADVM $1.78
- 52 Week High
- THCH $5.15
- ADVM $8.56
- Technical
- Relative Strength Index (RSI)
- THCH 49.97
- ADVM 66.10
- Support Level
- THCH $2.50
- ADVM $4.01
- Resistance Level
- THCH $2.74
- ADVM $5.58
- Average True Range (ATR)
- THCH 0.09
- ADVM 0.63
- MACD
- THCH 0.01
- ADVM 0.10
- Stochastic Oscillator
- THCH 48.00
- ADVM 71.60
About THCH TH International Limited Ordinary shares
TH International Ltd is the parent company of the franchise of Tim Hortons coffee shops and has the rights to operate Tim Hortons coffee shops in mainland China, Hong Kong, and Macau. Through the Tim Hortons brand, the firm offers freshly brewed coffee, tea, and other beverages, bakery & sides, and sandwiches. The Company operated under single reportable segment, Tim Hortons. The company's revenue is derived from its operations in the PRC.
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.